



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Dibutyl-cGMP sodium

Cat. No.:	HY-130354
CAS No.:	51116-00-8
Molecular Formula:	C ₁₈ H ₂₃ N ₅ NaO ₉ P
Molecular Weight:	507.37
Target:	Potassium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	-20°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H₂O : 100 mg/mL (197.09 mM; Need ultrasonic)
DMSO : 100 mg/mL (197.09 mM; Need ultrasonic)

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9709 mL	9.8547 mL	19.7095 mL
	5 mM	0.3942 mL	1.9709 mL	3.9419 mL
	10 mM	0.1971 mL	0.9855 mL	1.9709 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Dibutyl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analogue. Dibutyl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG). Dibutyl-cGMP sodium inhibits the release of [³H]-arachidonic acid from γ thrombin-stimulated human platelets. Dibutyl-cGMP sodium induces peripheral antinociception via activation of ATP-sensitive K⁺ channels^{[1][2][3]}.

IC₅₀ & Target

cGMP-dependent protein kinase (PKG)^[1];
ATP-sensitive K⁺ channels^[3]

In Vitro

Dibutyryl-cGMP is able to induce process elongation and branching in astrocytes resulting from a rapid, reversible and concentration-dependent redistribution of glial fibrillary acidic protein (GFAP) and actin filaments without significant change in protein levels^[1].

When cells are co-incubated with Dibutyryl-cGMP (100 μ M) stress fibre formation is prevented and cells acquired a stellate morphology in cerebellar astrocytes^[1].

In cells treated with Dibutyryl-cGMP (100 μ M, 2 h) the particulate fraction is nearly devoid of RhoA protein. Dibutyryl-cGMP prevents RhoA-membrane association^[1].

Using the scratchwound model, the size of the wound is significantly smaller in cells treated with Dibutyryl-cGMP after the wound indicating that dbcGMP accelerates wound closure^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Dibutyryl-cGMP (50-200 μ g/paw; subcutaneous injection; male Wistar rats) treatment antagonizes the hyperalgesic effect of PGE2 in a dose-dependent manner. Maximal antinociceptive effect of DbcGMP is at 1 h after administration and last for plus 2 h^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (180- 250 g) injection with Prostaglandin E2 (PGE2) ^[3]
Dosage:	50 μ g/paw, 75 μ g/paw, 100 μ g/paw and 200 μ g/paw
Administration:	Subcutaneous injection
Result:	Antagonized the hyperalgesic effect of PGE2 (2 μ g/paw), in a dose-dependent manner.

CUSTOMER VALIDATION

- Cell Oncol. 2023 Mar 20.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Borán MS, et al. The cyclic GMP-protein kinase G pathway regulates cytoskeleton dynamics and motility in astrocytes. J Neurochem. 2007 Jul;102(1):216-30.

[2]. Sane DC, et al. Cyclic GMP analogs inhibit gamma thrombin-induced arachidonic acid release in human platelets. Biochem Biophys Res Commun. 1989 Dec 15;165(2):708-14.

[3]. Soares AC, et al. Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K(+) channels in the rat PGE2-induced hyperalgesic paw. Br J Pharmacol. 2001 Sep;134(1):127-31.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA